Jacobio's KRAS G12C Drug Achieves Primary Study Goal

Jacobio Pharma's innovative KRAS G12C inhibitor, glecirasib, has demonstrated promising results in a Phase II study, as revealed at the recent ASCO Plenary Series. The study, led by Prof. Yuankai Shi from the Cancer Hospital Chinese Academy of Medical Sciences, reported remarkable efficacy in treating second-line non-small cell lung cancer (NSCLC) patients. The confirmed objective response rate (cORR) reached 47.9%, with 4 complete responses and 36 patients experiencing a significant tumor reduction. The disease control rate (DCR) was an impressive 86.3%.

The study also highlighted the drug's impact on survival rates, with a median progression-free survival (mPFS) of 8.2 months and median overall survival (mOS) of 13.6 months. Notably, the median duration of response (mDoR) has not been reached, with 6-month and 12-month response rates at 73.6% and 56.6%, respectively.

In terms of safety, glecirasib exhibited a favorable profile with no grade 5 treatment-related adverse events (TRAEs) and only a 5% discontinuation rate due to TRAEs. Its gastrointestinal (GI) profile is particularly advantageous compared to other KRAS G12C inhibitors.

Julia Rotow, MD, from the Dana-Farber Cancer Institute, noted that if glecirasib can outperform existing data while maintaining an improved side effect profile, it would be a compelling treatment option. The drug's unique toxicity profile could also allow for combinations with other agents that are not typically compatible with other KRAS G12C inhibitors.

Prof. Yuankai Shi emphasized the shift towards minimizing chemotherapy in lung cancer treatment. For patients with the KRAS G12C mutation who have not responded to first-line treatments, chemotherapy remains the primary second-line option in China. However, glecirasib has shown to be both more effective and safer, with an ORR of 14%, mPFS of 3.0 months, and OS of 9.1 months, compared to chemotherapy.

Glecirasib is currently under investigation in several Phase I/II clinical trials across China, the United States, and Europe for patients with advanced solid tumors with the KRAS G12C mutation. This includes pivotal trials in NSCLC, monotherapy studies for STK11 co-mutated NSCLC, and combination therapy trials with other drugs.

Jacobio Pharma, the developer of glecirasib, is dedicated to advancing health through innovative solutions. Their pipeline focuses on novel molecular targets across six major signaling pathways, aiming to be a global leader in drug R&D. With research centers in Beijing, Shanghai, and Boston, Jacobio employs cutting-edge platforms to drive their drug discovery efforts.